Stock XSPRAY XSPRAY PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:41 03/05/2024 BST 		5-day change 1st Jan Change
41.95 SEK +2.44% Intraday chart for Xspray Pharma AB +3.71% +4.88%
04-22 Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market CI
02-14 Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,394 3,665 1,326 1,293 1,250 1,311 - -
Enterprise Value (EV) 1 1,184 3,665 1,057 1,175 1,121 691.1 1,311 1,311
P/E ratio -27.6 x -63.6 x -12.7 x -9.12 x -5.92 x 1.96 x - -
Yield - - - - - 2.38% - -
Capitalization / Revenue - - - - - 10 x 1.66 x 0.82 x
EV / Revenue - - - - - 5.28 x 1.66 x 0.82 x
EV / EBITDA -28.3 x - -11.9 x -9.51 x -6.49 x -2.49 x 5.63 x 1.33 x
EV / FCF -9.38 x - -20 x - -5.44 x -1.81 x 14.6 x -
FCF Yield -10.7% - -5.01% - -18.4% -55.3% 6.86% -
Price to Book - - 2.24 x 2.33 x 1.53 x 0.69 x - -
Nbr of stocks (in thousands) 16,752 18,893 20,680 22,680 31,254 31,254 - -
Reference price 2 83.20 194.0 64.10 57.00 40.00 41.95 41.95 41.95
Announcement Date 28/02/20 25/02/21 18/02/22 15/02/23 14/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 131 789 1,605
EBITDA 1 -41.76 - -89.08 -123.5 -172.5 -278 233 986
EBIT 1 -46.56 - -97.95 -133.1 -181.7 -293 214 946
Operating Margin - - - - - -223.66% 27.12% 58.94%
Earnings before Tax (EBT) 1 -45.77 - -96.7 -131.7 -179.7 754.4 - -
Net income 1 -45.77 -52.41 -96.7 -131.7 -179.7 596 - -
Net margin - - - - - 454.97% - -
EPS 2 -3.010 -3.050 -5.030 -6.250 -6.760 21.42 - -
Free Cash Flow 1 -126.2 - -52.92 - -206 -382 90 -
FCF margin - - - - - -291.6% 11.41% -
FCF Conversion (EBITDA) - - - - - - 38.63% -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - 1.000 - -
Announcement Date 28/02/20 25/02/21 18/02/22 15/02/23 14/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales - - - - -
EBITDA 1 -49.98 -16.96 -26.82 -26.6 -53.16
EBIT 1 -52.28 -19.28 -29.21 -28.99 -55.59
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -51.94 -18.93 -28.86 -28.65 -55.22
Net income 1 -51.94 -18.93 -28.86 -28.65 -55.22
Net margin - - - - -
EPS 2 -2.620 -0.9200 -1.400 -1.390 -2.480
Dividend per Share - - - - -
Announcement Date 18/02/22 06/05/22 05/08/22 09/11/22 15/02/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 210 - 269 118 129 620 - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -126 - -52.9 - -206 -382 90 -
ROE (net income / shareholders' equity) -13.5% - - - - 55% - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 28.60 24.50 26.10 60.40 - -
Cash Flow per Share - - - - - - - -
Capex 1 23.1 - 1.31 - 2.69 26 28 -
Capex / Sales - - - - - 19.85% 3.55% -
Announcement Date 28/02/20 25/02/21 18/02/22 15/02/23 14/02/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
41.95 SEK
Average target price
107 SEK
Spread / Average Target
+155.07%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XSPRAY PHARMA AB Stock Xspray Pharma AB
+4.88% 121M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+313.59% 8.49B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XSPRAY Stock
  4. Financials Xspray Pharma AB